ALEXIS Biochemicals: Monoclonal Antibody to Ski (G8)

Advanced Search

You are here: Product Lines > Cancer > Tumor Markers

ALX-804-620

Revised 22-Apr-08

Monoclonal Antibody to Laminin Receptor Precursor (37kDa) (human) (MPLR2)
SYNONYMS	anti-37-kDa Laminin Receptor Precursor (human) MAb (MPLR2) anti-37LRP (human) MAb (MPLR2) anti-p40 Ribosome-associated Protein (human) MAb (MPLR2) anti-Multidrug Resistance-associated Protein MGr1-Ag (human) MAb (MPLR2)
PRODUCT LINE	Cytoskeleton
PRODUCT CATEGORY	Laminin/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-804-620-C100		100 µg	320.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	MPLR2
ISOTYPE:	Mouse IgG1
CONCENTRATION:	1mg/ml
FORMULATION:	Liquid. Purified antibody containing 150mM sodium chloride and 0.02% sodium azide, pH 7.4.
IMMUNOGEN:	Recombinant human 37kDa-laminin receptor precursor (37LRP).
SPECIFICITY:	Recognizes human 37kDa laminin receptor precursor. Depending on solubilization, can also recognize the 67kDa mature form of the laminin receptor (67LR) (see [1]). Detects a band of ~37kDa in Western blot.
APPLICATION:	Western Blot
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	+4°C
HANDLING:	Do not freeze.

Product Specific Literature References

[1] Production and characterization of monoclonal antibodies directed against the laminin receptor precursor: S. Buto, et al.; Int. J. Biol. Markers 12, 1 (1997) Abstract
[2] Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin: E. Ardini, et al.; J. Biol. Chem. 272, 2342 (1997) Abstract
[3] Formation of the 67-kDa laminin receptor by acylation of the precursor: S. Buto, et al.; J. Cell. Biochem. 69, 244 (1998) Abstract
[4] Laminin 5 in the human thymus: control of T cell proliferation via alpha6beta4 integrins: M. Vivinus-Nebot, et al.; J. Cell Biol. 144, 563 (1999) Abstract
[5] Human recombinant laminin-binding protein: isolation, purification, and crystallization: A.V. Sorokin, et al.; Biochemistry (Mosc). 65, 546 (2000) Abstract

General Information

The interactions between tumor cells and laminin or other components of the extracellular matrix have been shown to play an important role in tumor invasion and metastasis. They are mediated by different cell surface molecules such as the 67kD laminin receptor (67LR; laminin receptor 1), a protein derived from a smaller precursor, the 37LRP. In addition to its role as laminin receptor, 67LR also acts as a receptor for viruses and is involved with internalization of the prion protein.

General Literature References

The 67 kDa laminin receptor: structure, function and role in disease: J. Nelson, et al.; Biosci. Rep. 28, 33 (2008) Abstract; Full Text

Further Categories Containing This Product:

Tumor Markers • Prion Protein/Related Products • Monoclonal Antibodies

ALX-801-073

Revised 10-Jan-05

Monoclonal Antibody to Malignant Mesothelioma (human) (ME1)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	Tumor Markers

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-073-C025		25 µg	379.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	ME1
ISOTYPE:	Mouse IgG1
FORMULATION:	Lyophilized. Purified antibody.
IMMUNOGEN:	Mesothelioma cell line SPC111.
SPECIFICITY:	Recognizes a 200kDa surface membrane glycoprotein preferentially expressed on normal and malignant mesothelial cells. Does not cross-react with most lung adenocarcinoma cell lines or well and moderated differentiated pulmonary adenocarcinomas.
APPLICATION:	Immunocytochemistry Immunohistochemistry (frozen, acetone-fixed sections) Note: Not recommended for paraffin sections or ethanol- or formalin-fixation. Not recommended for Western blot.
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C

Product Specific Literature References

Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma: R. Stahel, et al.; Int. J. Cancer 41, 218 (1988) Abstract
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies: C. O'Hara, et al.; Am. J. Pathol. 136, 421 (1990) Abstract

Further Categories Containing This Product:

Monoclonal Antibodies

ALX-801-026

Revised 31-Oct-06

Monoclonal Antibody to MVP/LRP (human) (MVP-37)
SYNONYMS	anti-Major Vault Protein/Lung Resistance Protein (human) MAb (MVP-37)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	Major Vault Protein [MVP]/Lung Resistance Protein [LRP]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-026-C125		125 µg	350.00 USD
ALX-801-026-C250		250 µg	630.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	MVP-37
ISOTYPE:	Mouse IgG2b
CONCENTRATION:	~250µg/ml
FORMULATION:	Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN:	Human MVP/LRP (major vault protein/lung resistance protein).
SPECIFICITY:	Recognizes an internal epitope of human MVP/LRP, which is strongly overexpressed in various non-P-glycoprotein MDR tumor cell lines.
APPLICATION:	Immunohistochemistry (frozen sections, paraffin sections): use approx. 1:20-50 dilution for staining of paraformaldehyde (4%) fixed cytospin preparations or frozen tissue sections. Apply the following pretreatment: 10 min in 20mM glycine (pH 7.5) and 10 min in 6N guanidine hydrochloride in 50mM Tris-HCl, pH 7.5 (Schroeijers et al., 2000) Western Blot: use 1:50 dilution of MVP-37 (ECL)
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C

Product Specific Literature References

The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines: A.B. Schroeijers, et al.; Cancer Res. 60, 1104 (2000) Abstract; Full Text
Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies: A.B. Schroeijers, et al.; J. Histochem. Cytochem. 49, 1379 (2001) Abstract
Up-regulation of drug resistance-related vaults during dendritic cell development: A.B. Schroeijers, et al.; J. Immunol. 168, 1572 (2002) Abstract

Further Categories Containing This Product:

Tumor Markers • Monoclonal Antibodies

ALX-801-014

Revised 31-Oct-06

Monoclonal Antibody to MVP/LRP (human) (LMR5)
SYNONYMS	anti-Major Vault Protein /Lung Resistance Protein (human) MAb (LMR5)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	Major Vault Protein [MVP]/Lung Resistance Protein [LRP]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-014-C025		25 µg	350.00 USD
ALX-801-014-C050		50 µg	630.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	LMR5
ISOTYPE:	Rat IgG2a
CONCENTRATION:	~50µg/ml
FORMULATION:	Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN:	Human MVP/LRP (major vault protein/lung resistance protein).
SPECIFICITY:	Recognizes an internal epitope of human MVP/LRP, which is strongly overexpressed in various human non-P-glycoprotein MDR tumor cell lines.
APPLICATION:	Flow Cytometry (cell permeabilization required) Immunocytochemistry (cytospin preparations) Immunohistochemistry (frozen sections, paraffin sections) Recommended starting dilution is 1:20. Optimal conditions must be determined individually for each application.
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C

Product Specific Literature References

Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance: R.J. Scheper, et al.; Cancer Res. 53, 1475 (1993) Abstract
Membrane transport proteins associated with drug resistance expressed in human melanoma: D. Schadendorf, et al.; Am J. Pathol. 147, 1545 (1995) Abstract
The drug resistance-related protein LRP is the human major vault protein: G.L. Scheffer, et al.; Nature Med. 1, 578 (1995) Abstract
The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification: M.L. Slovak, et al.; Cancer Res. 55, 4214 (1995) Abstract
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors: M.A. Izquierdo, et al.; Am. J. Pathol. 148, 877 (1996) Abstract
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia: A.F. List, et al.; Blood 87, 2464 (1996) Abstract
Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia: M.L. Den Boer, et al.; Leukemia 11, 1078 (1997) Abstract
Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies: M.J. Flens, et al.; Int. J. Cancer 73, 249 (1997) Abstract
Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP: U. Stein, et al.; J. Natl. Cancer Inst. 89, 807 (1997) Abstract
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol. 103, 1083 (1998) Abstract
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia: M.L. Den Boer, et al.; Blood 91, 2092 (1998) Abstract; Full Text
Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma: H.G. Raaijmakers, et al.; Blood 91, 1029 (1998) Abstract; Full Text
Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues: A.B. Schroeijers, et al.; Am. J. Pathol. 152, 373 (1998) Abstract
Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma: H.J. Arts, et al.; Clin. Cancer Res. 5, 2798 (1999) Abstract; Full Text
Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma: M. Filipits, et al.; Clin. Cancer Res. 5, 2426 (1999) Abstract; Full Text
Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol. 52, 450 (1999) Abstract
Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines: V. Nuessler, et al.; Leukemia 13, 1864 (1999) Abstract
Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts: M. Pallis, et al.; Adv. Exp. Med. Biol. 457, 77 (1999) Abstract
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia: R. Pirker, et al.; Adv. Exp. Med. Biol. 457, 133 (1999) Abstract
Expression of the lung resistance protein (LRP) in primary breast cancer: G. Pohl, et al.; Anticancer Res. 19, 5051 (1999) Abstract
Multidrug resistance related proteins in primary cutaneous lymphomas: C.W. van Haselen, et al.; Adv. Exp. Med. Biol. 457, 119 (1999) Abstract
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells: G.K. Chen, et al.; Br. J. Cancer 83, 892 (2000) Abstract
Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas: M. Filipits, et al.; Clin. Cancer Res. 6, 3417 (2000) Abstract; Full Text
Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo: H. Kusakabe, et al.; Arch. Dermatol. Res. 292, 292 (2000) Abstract
Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas: D. Mayr, et al.; Pathol. Res. Pract. 196, 469 (2000) Abstract
Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies: A.B. Schroeijers, et al.; J. Histochem. Cytochem. 49, 1379 (2001) Abstract

Further Categories Containing This Product:

Tumor Markers • Monoclonal Antibodies

ALX-801-005

Revised 31-Oct-06

Monoclonal Antibody to MVP/LRP (human) (LRP-56)
SYNONYMS	anti-Major Vault Protein/Lung Resistance Protein (human) MAb (LRP-56)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	Major Vault Protein [MVP]/Lung Resistance Protein [LRP]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-005-C050		50 µg	350.00 USD
ALX-801-005-C100		100 µg	630.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	LRP-56
ISOTYPE:	Mouse IgG2b
CONCENTRATION:	~250µg/ml
FORMULATION:	Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN:	Human MVP/LRP (major vault protein/lung resistance protein).
SPECIFICITY:	Recognizes an internal epitope (P110) of human MVP/LRP, which is overexpressed in various human non-P-glycoprotein MDR tumor cell lines.
APPLICATION:	Flow Cytometry (cell permeabilization required) Immunocytochemistry (cytospin preparations) Immunohistochemistry (frozen sections, paraffin sections). Recommended starting dilution is 1:20. Optimal conditions should be determined individually for each application.
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C
POSITIVE CONTROL:	Cell lines: Appropriate drug-sensitive parental cell lines and their multdrug resistant derivatives prepared by the same methods as the test specimens should be used as control materials. Tissue: Human colon, kidney, bronchus or adrenal are recommended.

Product Images

Please click on thumbnails to enlarge.

Product Specific Literature References

Further Categories Containing This Product:

Tumor Markers • Monoclonal Antibodies

ALX-804-186

Revised 04-Sep-07

Monoclonal Antibody to p53 (phosphorylated) (pSer392) (9F4)
PRODUCT LINE	Cell Cycle
PRODUCT CATEGORY	p53 Antibodies

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-804-186-C100		100 µg	453.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human Mouse
CLONE:	9F4
ISOTYPE:	Mouse IgG1
PURITY DETAIL:	Purified from serum-free cell culture supernatant by subsequent thiophilic adsorption and size exclusion chromatography.
FORMULATION:	Lyophilized from 1ml 2x PBS, 0.1% sodium azide, PEG and sucrose.
RECONSTITUTION:	Reconstitute with 1 ml distilled water (15 min, RT).
IMMUNOGEN:	Synthetic peptide corresponding to a portion of p53 phosphorylated at Ser³⁹².
SPECIFICITY:	Recognizes activated human p53 phosphorylated at Ser³⁹². Does not cross-react with the non-phosphorylated form of p53 or with unrelated serine-phosphorylated proteins.
APPLICATION:	Western Blot: 1µg/ml for AP/BCIP/NBT (MTT) detection; 0.1µg/ml for HRPO/ECL detection. Do not use milk/casein for blocking and dilution! Replace by BSA!
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Reconstituted antibody is stable for 1 year when stored at -80°C. Thaw aliquots at +37°C. Thawed aliquots may be stored at +4°C for up to 3 months.
HANDLING:	Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and freeze in liquid nitrogen.

Further Categories Containing This Product:

Phospho-specific Antibodies • Tumor Markers • Monoclonal Antibodies

ALX-801-002

Revised 16-Jun-08

Monoclonal Antibody to P-glycoprotein (C219)
SYNONYMS	anti-ABCB1 MAb (C219) anti-CD243 MAb (C219)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	P-glycoprotein [Pgp]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-002-C100		100 µg	690.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human Mouse Rat Others
CLONE:	C219
ISOTYPE:	Mouse IgG1
CONCENTRATION:	100µg/ml
FORMULATION:	Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN:	SDS-solubilized plasma membranes of an MDR (multidrug resistant) Chinese hamster ovary (CHO) cell line and a human cell line.
SPECIFICITY:	Recognizes an internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in both protein isoforms, P-glycoprotein and MDR3 P-glycoprotein; not species specific.
CROSSREACTIVITY PROTEINS:	Cross-reacts with a ~200kDa protein which migrates in the same position as myosin and with C-erbB2 protein (p185^c-erbB2).
APPLICATION:	Flow Cytometry (cell permeabilization required) Immunocytochemistry (cytospin preparations) Immunohistochemistry (frozen sections, paraffin sections) Immunoprecipitation Western Blot (1:50-1:100). Optimal conditions must be determined individually for each application. Recommendations for Immunohistochemistry on paraffin sections: - For optimal staining, the sections should be pretreated with an antigen unmasking solution. - The antibody may be diluted to ≥1:25 for biotin based detection systems. - For optimal staining, the primary antibody should be incubated 60 minutes at room temperature.
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C
HANDLING:	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Product Specific Literature References

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature 316, 820 (1985) Abstract
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines: H.S. Chan, et al.; Lab. Invest. 59, 870 (1988) Abstract
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991) Abstract
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol. 140, 1009 (1992) Abstract
New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues: K. Toth et al.; Am. J. Pathol. 144, 227 (1994) Abstract
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996) Abstract
MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res. 2, 1231 (1996) Abstract
P-glycoprotein expression and prognostic value in acute myeloid leukemia: L. Senent, et al.; Haematologica 83, 783 (1998) Abstract
Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil: L. Candussio, et al.; Anticancer Res. 19, 1101 (1999) Abstract
Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport: E. Crivellato, et al.; Histochem. J. 31, 635 (1999) Abstract
Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study: C. Dhooge & B. De Moerloose; Adv. Exp. Med. Biol. 457, 11 (1999) Abstract
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme: R. Durmaz, et al.; Clin. Neurol. Neurosurg. 101, 238 (1999) Abstract
Interferon α2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer. Res. Clin. Oncol. 125, 117 (1999) Abstract
A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin: S.M. Hahn, et al.; Int. J. Oncol. 14, 273 (1999) Abstract
Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin: K. Kawazu, et al.; Invest. Ophtalmol. Vis. Sci. 40, 1738 (1999) Abstract
Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein: J.M. van Den Elsen, et al.; PNAS 96, 13679 (1999) Abstract; Full Text
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells: H. Wada, et al.; Exp. Hematol. 27, 99 (1999) Abstract
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival: H. Yokoyama, et al.; Surg. Today 29, 1141 (1999) Abstract
P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries: M. Demeule, et al.; FEBS Lett. 466, 219 (2000) Abstract
Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity: M. Julien & P. Gros; Biochemistry 39, 4559 (2000) Abstract
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol. 113, 355 (2000) Abstract
Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry 39, 3424 (2000) Abstract
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart: A. Rosati, et al.; Anticancer Res. 20, 3403 (2000) Abstract
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000) Abstract; Full Text
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem. 275, 1887 (2000) Abstract; Full Text
Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart: G. Decorti, et al.; Biochem. Pharmacol. 61, 61 (2001) Abstract
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone: R. Yumoto, et al.; Drug. Metab. Dispos. 29, 145 (2001) Abstract; Full Text

Further Categories Containing This Product:

CD Antibodies • Tumor Markers • Monoclonal Antibodies

ALX-801-001

Revised 22-Feb-05

Monoclonal Antibody to P-glycoprotein (human) (4E3.16)
SYNONYMS	anti-ABCB1 (human) MAb (4E3.16) anti-CD243 (human) MAb (4E3.16)
PRODUCT LINE	Cancer
PRODUCT CATEGORY	P-glycoprotein [Pgp]/Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-801-001-C050		50 µg	790.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
CLONE:	4E3.16
ISOTYPE:	Mouse IgG2a
CONCENTRATION:	~0.05mg/ml
FORMULATION:	Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN:	MDR (multidrug resistant) human squamous lung cancer cell line SW-1573/500 (doxorubicin resistant) and MDR human uterine adenocarcinoma cell line ME180/DOX 500 (doxorubicin resistant).
SPECIFICITY:	Recognizes an external epitope of human P-glycoprotein. Does not cross-react with human MDR3 P-glycoprotein.
APPLICATION:	Flow Cytometry Immunocytochemistry Immunohistochemistry (frozen sections; not recommended for paraffin sections) Immunoprecipitation. Note: Not recommended for Western blot.
SHIPPING:	SHIPPED ON BLUE ICE
SHORT TERM STORAGE:	+4°C
LONG TERM STORAGE:	-20°C
HANDLING:	Avoid freeze/thaw cycles.
POSITIVE CONTROL:	Cell lines: Appropriate drug-sensitive parental cell lines and their multidrug resistant derivatives prepared by the same methods as the test specimens can be used as control materials. Tissue: Liver (positive staining detected along luminal surfaces of bile canaliculi) or colon (positive staining localized to luminal surface of secretory epithelium).

Product Specific Literature References

Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein: R.J. Arceci, et al.; Cancer Res. 53, 310 (1993) Abstract
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996) Abstract
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network: S. Huet, et al.; Cytometry 34, 248 (1998) Abstract
Identification of a multidrug resistance-like system in Tetrahymena pyriformis: evidence for a new detoxication mechanism in freshwater ciliates: M. Bamdad, et al.; FEBS Lett. 456, 389 (1999) Abstract
Discordance of P-glycoprotein expression and function in acute leukemia: B. De Moerloose, et al.; Adv. Exp. Med. Biol. 457, 107 (1999) Abstract
Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines: V. Nuessler, et al.; Leukemia 13, 1864 (1999) Abstract
Conformational heterogeneity of P-glycoprotein: K. Goda, et al.; Cancer Detect. Prevent. 24, 415 (2000) Abstract
Functional characterization of glycosylation-deficient human P-glycoprotein using A vaccinia virus expression system: J.J. Gribar, et al.; J. Membr. Biol. 173, 203 (2000) Abstract
Simult